ESR1 and breast neoplasm: Subsequent studies reported that XBP1s expression in ER+ breast tumors correlated with poor clinical responsiveness to tamoxifen, however, the underlying signaling mechanisms affected by XBP1s, as well as the effects of splicing on anti-estrogen resistance, remain unclear.